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introduction
Zika is a mosquito-borne Flavivirus which is transmitted 
to humans through the bite of infected mosquitoes from the 
Aedes genus. It was first discovered in 1941 and has since 
caused sporadic disease in Africa and Asia. Zika recently 
caught the media’s attention  following an outbreak that 
started in Brazil in May 2015.1 It was during this outbreak 
that Zika virus was linked to an increased incidence of the 
birth defect known as microcephaly, which results in babies 
born with abnormally small heads and central nervous system 
malformations. Zika was confirmed as a threat to pregnant 
women after laboratory research demonstrated its detrimental 
effects on developing nerve cells in foetuses.2 It has also been 
linked to Guillian Barré syndrome.3
 Since the start of the 2015 outbreak this virus has spread 
geographically to Latin America, the Caribbean and parts of 
Oceania. Currently, 61 countries and territories are experiencing 
ongoing Zika transmission while over seven hundred cases of 
travel-associated Zika have been reported in a total of ten EU 
countries since May 2015.4 On 1st February 2016, the World 
Health Organisation declared Zika virus a Public Health 
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Emergency of International Concern (PHEIC) under the 
International Health Regulations (2005)5 due to emerging data 
linking this virus to transplacental infections, adverse foetal 
outcomes, congenital CNS malformations and neurological 
complications as mentioned above.6 
clinical features
 The incubation period for Zika virus is 3 to 7 days, with only 
20% of those infected going on to develop clinical symptoms.7 
The symptoms of Zika virus are similar to those caused by other 
arboviruses such as Dengue and Chikungunya, and include low-
grade fever, maculopapular rash, conjunctivitis, fatigue, myalgia 
and arthralgia.6 The symptom most characteristic of Zika virus 
infection is maculopapular rash.6 Symptoms usually last 7-10 
days and are mild, self-limiting and non-specific. Zika virus is 
known to be detectable for at least 7 days after development of 
symptoms in blood, at least two weeks in urine and at least 2 
months in semen.8 It has also recently been detected in vaginal 
secretions.9 Diagnosis is carried out using RT-PCR techniques.
Mode of transMission
Zika is a vector-borne disease which is most commonly 
transmitted via the bite of an infected Aedes Aegypti mosquito. 
However, studies have shown that Aedes Albopictus, commonly 
known as the Asian Tiger mosquito, can also transmit this virus. 
Other modes of transmission include:
1. Vertical transmission from mother to child during 
pregnancy or childbirth;
2. Transmission via blood transfusion;
3. Transmission from a sexual partner.
health promotIon
15Volume 15, 2016  Issue 04
Job no.: MLT_GIB/CBP/0001/15     Date of preparation: January 2016
• More patients with mild to moderate acne achieved at least a 30% reduction in inﬂ ammatory and non-inﬂ ammatory lesion 
counts at week 2 with Duac than Erythromycin-zinc complex1
• DUAC demonstrated a faster onset of action, reducing total lesion count in signiﬁ cantly more patients than Erythromycin-zinc 
complex at just 2 weeks1
• Most common side effects include erythema, peeling, dryness, burning sensation, photosensitivity and headache
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Graphs adapted from Langner A et al. JEADV 2007
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DUAC INDICATIONS 
& USAGE ADVICE2
• Duac Once Daily Gel is indicated for the topical treatment of mild to moderate acne vulgaris, 
particularly inﬂ ammatory lesions in adults and adolescents from 12 years of age and above2
• Formulation contains added moisturisers, glycerin and dimethicone, for better tolerability4
YOUR EXPERT ADVICE CAN SHOW ON THEIR FACE
Duac comes ready-mixed, and is easy for your patients to use. It is recommended that you offer the following guidance3:
Once-daily, in the evening, your patients should2:
•  Thoroughly wash the 
affected area of skin
•  Gently pat dry •  Apply a thin layer of Duac 
gel on the affected area, 
not just the individual spots
TIPS3
If your patient’s skin peels or becomes dry, they can try:
•  Using an oil and fragrance-free hypoallergenic moisturiser
•  Using Duac less often, or stopping for one or two days before starting again
HEAD TO HEAD, DUAC WORKS FASTER THAN
ERYTHROMYCIN-ZINC COMPLEX1
Duac® Once Daily 10mg/g + 50mg/g Gel Abridged Prescribing Information
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in patients with a history of regional enteritis, ulcerative colitis and antibiotic-associated colitis. 
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immediately discontinued. Resistance to clindamycin: Patients with a recent history are more 
likely to have pre-existing anti-microbial resistant Propionibacterium acnes and commmensal 
ﬂ ora. Cross-resistance: May occur when using antibiotic monotherapy. Fertility, Pregnancy and 
Lactation: There is no adequate data. Avoid application of the product to the breast area. 
Effect on Ability to Drive or Use Machines: No studies. Side Effects: Very Common side effects 
(at least 1 in 10) include erythema, peeling and dryness. Common side effects (less than 1 in 
10) include burning sensation, photosensitivity and headache. Overdose: No speciﬁ c antidote. 
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The latest information regarding sexual transmission of Zika 
virus is based on a recent report documenting a case of female-
to-male Zika virus transmission and confirming the detection of 
Zika RNA in vaginal secretions.10 Male-to-female and male-to-
male transmission has been already documented. This recent 
discovery implies that any type of sexual activity (be it vaginal, 
anal, oral, or contact with genital secretions) can lead to Zika 
exposure in sexual partners of both male and female individuals 
who are infected with Zika virus. All those who can potentially 
be infected with Zika (males and females) are advised to 
consistently and correctly use male or female condoms for 
vaginal and anal sex. Attention should be paid when sharing sex 
toys. Appropriate barriers should also be used for oral sex.11  
WHO now recommends that travellers to Zika-affected 
countries should delay conception and abstain from sex or 
practice safe sex for a period of at least eight weeks after their 
return if they do not develop any symptoms suggestive of 
Zika virus infection. Individuals who do develop symptoms 
compatible with Zika virus infection or for whom Zika 
infection has been confirmed by laboratory testing should delay 
conception and abstain or practice safer sex for six months after 
recovery.12 Pregnant women with male or female sex partners 
who live in or have travelled to a Zika-affected country are 
advised to abstain from sex or consistently practice safer sex for 
the duration of the pregnancy.9
preventive Measures
There is no existing licensed vaccine or specific treatment 
for the Zika virus available. However, research into vaccine 
development is ongoing. A DNA plasmid vaccine known as GLS-
5700 was granted US Food and Drug Administration approval for 
a Phase 1 safety trial in human volunteers in June, while another 
two candidate vaccines have shown promising results in mice.13 
Preventive measures centre on personal protection from mosquito 
bites, avoiding pregnancy while in Zika-affected areas and 
postponing travel to these areas if pregnant. Travellers returning 
from Zika-affected countries are deferred from donating blood at 
the National Blood Transfusion Service for a period of four weeks. 
The following advice is taken from the Infectious Disease 
Control Unit’s publication: ‘Information for People Travelling to 
Zika-affected areas’ and relates to personal protective measures 
against mosquito bites.14
1. Protect skin from exposure to mosquitoes by wearing long 
sleeves, long trousers and hats.
2. Use mosquito repellent that has DEET as an ingredient (30-
50% concentration for those above 2 years of age including 
pregnant women, 20% concentration for children under 
2 years). Repellents may be applied to exposed skin or to 
clothing. Repellents are safe to use during pregnancy and in 
infants older than 3 months. Repellents need to be applied 
at regular intervals and must be used in strict accordance 
with the instructions indicated on the product label, 
especially regarding duration of protection and frequency 
of reapplication. If a traveller is applying both sunscreen 
and insect repellent, the sun screen should be applied first, 
followed by the insect repellent.
3. Use physical barriers such as mosquito screens on doors 
and windows.
4. Sleep in closed air-conditioned accommodation or under 
insecticide-treated mosquito netting especially when resting 
during the day, when Aedes mosquitoes are most active.
5. Eliminate any possible mosquito breeding sites, such as 
standing collections of water while staying in a Zika-
affected country.
tHe local situation
Aedes albopictus (Asian Tiger mosquito), a potential vector 
for Zika virus, is known to be present on the Maltese Islands.15 
There is, however, no evidence to suggest that our local 
mosquito population is infected with Zika virus.16 The public 
health authorities are preparing a national plan on mosquito-
borne diseases and surveillance of mosquitoes is being enacted.
Zika has recently been declared a notifiable disease in Malta 
together with Dengue, Chikungunya and West Nile fever.17 
Testing for all these vector-borne diseases is now possible locally. 
Symptomatic returning travellers are obliged to contact public 
health authorities no later than the day after their return so that 
the necessary precautions are taken and testing is carried out.
An awareness campaign is also being carried out with the 
general public. This includes social media updates, information 
leaflets and posters encouraging individuals to contribute to 
vector control. Posters have also been set up at the airport and 
seaport with information for outgoing and returning travellers. 
Detailed advice for travellers to Zika-affected areas and 
travellers to the Rio Olympics, as well as further information 
on Zika virus, is available on the Infectious Disease Prevention 
and Control Unit’s (IDCU) website. Those requiring further 
information can contact the Zika helpline on 21324086.  
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IDCU website link: http://health.gov.mt/en/health-promotion/
idpcu/Pages/introduction.aspx
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